欢迎分享，转载有版权, 快快登录 lingmed.net/reports 下载全文吧！
LMP1098 治疗骨关节炎
骨关节炎（osteoarthritis）是一种退行性病变，多种因素导致的关节软骨退化，损伤及软骨下骨的反应性增生。作为关节炎最常见的一种形式，骨关节炎约影响全球2.37亿人（3.3%）。且随着年龄的增加，不管是男性还是女性，发病率都显示持续增加的趋势。在60岁以上的人群中，约10%的男性与18%的女性会受到影响。
根据EvaluatePharma预估医药数据库显示，2016年全球骨关节炎历史销售额高达17.35亿美金，重磅药Synvisc为主要贡献力量。预测2022年，现处于上市申请阶段的Zilretta将在其上市之后瓜分相当分量的市场份额，而总骨关节炎市场将达20.14亿美金（顶级投行综合性预测）。
LMP1098项目优势及创新性总结
1. 可提高细胞功能性及改善治疗效果的MSCs生物活性分泌物
2. 1期临床试验证明其安全性及有效性
3. 1期临床试验证明其可以快速且持续的改善关节疼痛，增加软骨量并有修复并改善疾病
4. 已授权日本AGC公司为日本市场独家生产商，正积极寻求中国独家伙伴
如需项目接洽或者更详细的项目非保密资料，请联系我们info@lingmed.net 或登录www.lingmed.net/reports 查询其他项目信息。
LMP1098 for Osteoarthritis
Osteoarthritis (OA) is a type of joint disease that results from breakdown of joint cartilage and underlying bone. The most common symptoms are joint pain and stiffness. Osteoarthritis is the most common form of arthritis affecting about 237 million (3.3%) of the population. Among those over 60 years old, about 10% of males and 18% of females are affected. It becomes more common in both sexes as people become older.
According to EvaluatePharma database, the historic 2016 sales for Oestaorithsis have reached 1.735 billion USA dollars with the major driver comes from Synvisc. Outlook to 2022, we see Zilretta (Field) will pick up significant market share in 2022 with the total Oestaorithsis increase to 2.014 billion USA dollars (by consensus forecast of Top6 Investment banks).
LMP1098 Asset Highlight
1. MSCs secretion which can improve functionality of cells and therapeutic effect.
2. Phase I clinical trials show great safety and tolerability
3. Phase I clinical trials show rapid and sustained knee pain reduction, significant improvement in cartilage volume and positive signs of disease modification.
4. Collaborate with AGC for exclusive manufacturer in Japan and look for partners in China
If you interested in this innovative asset, please contact us info@lingmed.net or visit www.lingmed.net/reports for more available assets.
想要下载完整报告?
请登录 www.lingmed.net/reports
或点击下方“阅读原文”马上下载
